Antidepressant-Associated Sleep Disorders

Introduction to Antidepressant-Associated Sleep Disorders

Antidepressants, including selective serotonin reuptake inhibitors (SSRIs) like paroxetine and fluoxetine, as well as other antidepressants such as venlafaxine, mirtazapine, and imipramine, have been associated with REM sleep behavior disorder (RBD) and Raynaud's phenomenon, according to the American Academy of Sleep Medicine 1

Raynaud's phenomenon is associated with connective tissue disorders, such as systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis, as well as vascular pathologies, including atherosclerosis and thromboangiitis obliterans (Buerger's disease), according to the American Heart Association and the American College of Cardiology 2
Hematological disorders, such as prothrombotic states and hyperhomocysteinemia, can also contribute to Raynaud's phenomenon, as reported by the American Heart Association 2
Other causes, including medication-induced, occupational exposure to vibration, endocrine disorders, and malignancies, can also lead to Raynaud's phenomenon, according to the American College of Cardiology 2

The American College of Cardiology recommends using Doppler ultrasound of the upper limb arteries to exclude obstructive vascular disease 3
Raynaud's phenomenon typically presents as episodic color changes in digits, including a white phase (pallor), a blue phase (cyanosis), and a red phase (erythema), as described by the American Academy of Dermatology and the American Heart Association 2
Pain and/or paresthesia due to sensory nerve ischemia, as well as attacks triggered by cold exposure, emotional stress, or vasoconstrictive drugs, are also common symptoms of Raynaud's phenomenon, as reported by the American Heart Association 2

Avoiding cold exposure and implementing protective measures, such as wearing gloves and mittens, is recommended for people with Raynaud's phenomenon, particularly those with systemic sclerosis (SSc), as advised by the European League Against Rheumatism and the American College of Rheumatology 4, 5
Avoiding other known triggers, such as stress, smoking, and vibration injury, is also advised, as well as using gloves when handling cold items and avoiding direct contact with cold surfaces 4, 5
Exercise improves hand function and physical capacity in SSc patients with Raynaud's, and should be considered as part of non-pharmacological management, as recommended by the European League Against Rheumatism and the American College of Rheumatology 5

Calcium channel blockers (CCBs) are strongly recommended as first-line therapy, with nifedipine (extended-release formulation) being typically used, as recommended by the European League Against Rheumatism and the American College of Rheumatology 4, 5
Phosphodiesterase-5 (PDE5) inhibitors, such as sildenafil and tadalafil, can improve and reduce digital ulcers, and may be considered as alternative treatments for patients who fail or cannot tolerate CCBs, as recommended by the European League Against Rheumatism and the American College of Rheumatology 4, 5
Bosentan, an endothelin receptor antagonist, can prevent new digital ulcers but does not improve healing of existing ulcers, as reported by the American College of Rheumatology 4
Intravenous prostacyclin analogues, such as iloprost, are the most promising treatment for secondary Raynaud's with digital ulcers or critical ischemia, as recommended by the American College of Rheumatology 5

Digital ulcers in Raynaud's disease have a high risk of progression to gangrene (22.5%) and osteomyelitis (11%), requiring vigilant monitoring, according to the American College of Rheumatology 4
Antibiotics should only be prescribed when infection is suspected in chronic digital ulcers associated with Raynaud's disease, not as routine treatment for uninfected ulcers, as recommended by the American College of Rheumatology 4
First-line empiric therapy for infected digital ulcers in Raynaud's disease includes Amoxicillin-clavulanate OR Cephalexin plus metronidazole, as suggested by the American College of Rheumatology 4
For suspected MRSA or penicillin allergy, Trimethoprim-sulfamethoxazole OR Doxycycline should be considered, based on guidelines from the Infectious Diseases Society of America 4
Regular assessment for complications, including digital ulcers, is necessary for secondary Raynaud's, and treatment response should be monitored by tracking frequency and severity of attacks, as recommended by the European League Against Rheumatism and the American College of Rheumatology 4, 5

Mild-moderate infections should be treated with antibiotics for 7-10 days, while severe infections or those with underlying osteomyelitis require 2-6 weeks of therapy, according to the American College of Rheumatology 4
Most pharmacological treatments are effective in less than 50% of patients, and medications typically reduce severity and frequency of attacks rather than completely eliminating them, highlighting the need for ongoing monitoring and adjustment of treatment plans, as reported by the American College of Rheumatology 5